Pfizer Licenses Halozyme's Enhanze Technology

Pfizer (NYSE: PFE  ) has licensed Halozyme Therapeutics' (NASDAQ: HALO  ) Enhanze technology, which the pharmaceutical giant plans to combine with its biologics. The technology allows drugs that would otherwise have to be administered intravenously or require multiple injections to be delivered subcutaneously -- just below the surface of the skin.

Two therapeutic targets in primary care and specialty care indications have already been identified, for which Pfizer will pay Halozyme $8 million. The license also allows Pfizer to select four additional targets upon payment of additional undisclosed fees.

Halozyme is eligible to receive additional payments of up to $507 million if Pfizer achieves specific development, regulatory, and sales-based milestones.

The biotech has licensed the Enhanze technology to four other companies: Baxter (NYSE: BAX  ) , Roche (NASDAQOTH: RHHBY  ) , Viropharma (NASDAQ: VPHM  ) , and Interexon.

link


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2166551, ~/Articles/ArticleHandler.aspx, 8/22/2014 8:09:18 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement